224 related articles for article (PubMed ID: 38012666)
1. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
[TBL] [Abstract][Full Text] [Related]
3. The role of metabolic imaging in radiation therapy of prostate cancer.
Zhang VY; Westphalen A; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2014 Jan; 27(1):100-11. PubMed ID: 23940096
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
[TBL] [Abstract][Full Text] [Related]
5. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.
Keshari KR; Tsachres H; Iman R; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2011 Jul; 24(6):691-9. PubMed ID: 21793074
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
8. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.
Vandergrift LA; Decelle EA; Kurth J; Wu S; Fuss TL; DeFeo EM; Halpern EF; Taupitz M; McDougal WS; Olumi AF; Wu CL; Cheng LL
Sci Rep; 2018 Mar; 8(1):4997. PubMed ID: 29581441
[TBL] [Abstract][Full Text] [Related]
10. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS
Madhu B; Shaw GL; Warren AY; Neal DE; Griffiths JR
Metabolomics; 2016; 12():120. PubMed ID: 27429605
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.
Huynh MJ; Gusev A; Palmas F; Vandergrift L; Berker Y; Wu CL; Wu S; Cheng LL; Feldman AS
Urol Oncol; 2023 Nov; 41(11):459.e9-459.e16. PubMed ID: 37863744
[TBL] [Abstract][Full Text] [Related]
12. Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues.
Wang S; Wen S; Guo P; Liu H; Feng J; Huang H
J Pharm Biomed Anal; 2020 Oct; 190():113546. PubMed ID: 32846403
[TBL] [Abstract][Full Text] [Related]
13. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.
Cheng LL; Burns MA; Taylor JL; He W; Halpern EF; McDougal WS; Wu CL
Cancer Res; 2005 Apr; 65(8):3030-4. PubMed ID: 15833828
[TBL] [Abstract][Full Text] [Related]
14. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.
Giskeødegård GF; Bertilsson H; Selnæs KM; Wright AJ; Bathen TF; Viset T; Halgunset J; Angelsen A; Gribbestad IS; Tessem MB
PLoS One; 2013; 8(4):e62375. PubMed ID: 23626811
[TBL] [Abstract][Full Text] [Related]
15. Grading of endometrial cancer using
Skorupa A; Poński M; Ciszek M; Cichoń B; Klimek M; Witek A; Pakuło S; Boguszewicz Ł; Sokół M
Sci Rep; 2021 Sep; 11(1):18160. PubMed ID: 34518615
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic signatures of aggressive prostate cancer.
McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic studies of patient material by high-resolution magic angle spinning nuclear magnetic resonance spectroscopy.
Keun H
Methods Enzymol; 2014; 543():297-313. PubMed ID: 24924139
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of patients with and without prostate cancer using urine
Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
[TBL] [Abstract][Full Text] [Related]
19. Impact of real-time metabolomics in liver transplantation: Graft evaluation and donor-recipient matching.
Faitot F; Besch C; Battini S; Ruhland E; Onea M; Addeo P; Woehl-Jaeglé ML; Ellero B; Bachellier P; Namer IJ
J Hepatol; 2018 Apr; 68(4):699-706. PubMed ID: 29191459
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
